Accepted at 12:41 a.m. Nov, 01, 2023 by dollajas
Author: CobrakMD
Related Note: 1577747155744
Rationale for change

Indomethacin is indicated in pre term labor at < 32 weeks.
As such these complications are seen in at <32 weeks.

QID uworld - 17429 for reference

Text Text
Extra
- Decreased production of prostaglandins leads to fetal vasoconstriction and subsequent decreased renal perfusion = oligohydramnios

- Particularly with prolonged administration; therefore, patients typically receive indomethacin for <48 hours

- Oligohydramnios is typically transient and resolves without intervention once the medication is discontinued
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
Empty field
OME

Additional Resources
Empty field
One by one
Empty field
#AK_Step2_v12::#UWorld::COMLEX::103763 #AK_Step2_v12::#B&B::11_Obstetrics_and_Gynecology::01_Obstetrics::01_Normal_Pregnancy::Extra #AK_Step2_v12::!Shelf::#Cards_AnKing_Did::2obgyn #AK_Step2_v12::#SketchyPeds::04_Cardiology::01_Congenital_Heart_Disease::07_Acyanotic_Congenital_Heart_Disease_DDx #AK_Step2_v12::#UWorld::Step::17429 #AK_Step2_v12::#SketchyOBGYN::02_Pregnancy_Complications::02_Fetal_Complications_of_Pregnancy::05_Amniotic_Fluid_Disorders !AK_UpdateTags::Step2decks::Cheesy-Dorian-(M3)::OBGYN::4-UWorld #AK_Step2_v12::#B&B::11_Obstetrics_and_Gynecology::01_Obstetrics::17_Labor_and_Delivery_Complications::Extra #AK_Step2_v12::Original_decks::Dorian::obgyn::uw #AK_Step2_v12::#SketchyOBGYN::01_Prenatal_Care_&_Early_Pregnancy::01_Intro_to_OB::03_Fetal_Physiology #AK_Step2_v12::#B&B::11_Obstetrics_and_Gynecology::01_Obstetrics::16_Preterm_Labor::Extra #AK_Step2_v12::#Resources_by_rotation::ObGyn::uw::dorian #AK_Step2_v12::!Shelf::ObGyn::no_dupes #AK_Step2_v12::#Subjects::Cardiology::01_Embryology::Patent_Ductus_Arteriosus #AK_Original_Decks::Step_2::Cheesy_Dorian_(M3) #AK_Step2_v12::!Shelf::ObGyn::no_dupes::only_step2 #AK_Step1_v12::#OME::PreClinical::Biochemistry